system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Acetylation, Antineoplastic Combined Chemotherapy Protocols, Apoptosis, Apoptosis Regulatory Proteins, Autophagy, Beclin-1, Carcinoma, Hepatocellular, Cell Cycle Checkpoints, Cell Proliferation, Dose-Response Relationship, Drug, Drug Synergism, Gene Expression Regulation, Neoplastic, Hep G2 Cells, Histone Deacetylase Inhibitors, Humans, Hydroxamic Acids, Liver Neoplasms, Membrane Proteins, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, RNA Interference, Sorafenib, Transfection, Tumor Suppressor Protein p53, Vorinostat.
user
Does inhibition of autophagy signiﬁcantly enhance combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells? Context: To clarify whether histone deacetylase inhibitors histone deacetylase inhibitors (HDACIs) can sensitize hepatocellular carcinoma (HCC) cells to sorafenib treatment. Bax, Bcl-2, ATG5-ATG12, p21, and p27 protein levels in Hep3B, HepG2, and PLC/PRF/5 cells were examined by Western blot. CCK8 and a fluorometric caspase-3 assay were used to examine cellular viability and apoptosis levels. The effect of Beclin-1 on sensitization of HCC cells to sorafenib was examined by transfecting Beclin-1 siRNA into Hep3B, HepG2, and PLC/PRF/5 cells. Autophagy inhibition enhances the inhibitory effects of vorinostat and sorafenib alone or in combination on HCC cell growth. Vorinostat and sorafenib synergistically induced apoptosis and cell cycle alterations. Western blot data indicated that HDACIs and Beclin-1 knockdown increased the p53 acetylation level. The knockdown of Beclin-1 enhanced the synergistic effect of the combination of vorinostat with sorafenib.
assistant
HDACIs can sensitize HCC cells to sorafenib treatment by regulating the acetylation level of Beclin-1. Final Decision: yes